The emergence of immune checkpoint inhibitors as effective cancer immunotherapy has effectively built a new “highway” connecting the promise of oncologic translational research to progress in treating advanced malignancies.
Matthew Zibelman, MD
Advertisement
Articles by Matthew Zibelman, MD
Advertisement
Latest Updated Articles
- Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm
Published: February 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
